Advertisement

Advertisement

Quick Chats

hematologic malignancies
immunotherapy

By The ASCO Post Staff  / Quick Chats

Andrew D. Zelenetz, MD, PhD, and Stephen J. Schuster, MD, on CAR T Cells for Hematologic Malignancies: Where We’re At

multiple myeloma

By The ASCO Post Staff  / Quick Chats

Paul G. Richardson, MD, and Peter M. Voorhees, MD, on Multiple Myeloma: Surveying the Evolving Landscape of Up-Front Drugs

colorectal cancer
gastrointestinal cancer

By The ASCO Post Staff  / Quick Chats

Heinz-Josef Lenz, MD, and Axel Grothey, MD, on Liquid Biopsies for Colorectal and Other GI Cancers

colorectal cancer
genomics/genetics

By The ASCO Post Staff  / Quick Chats

Heinz-Josef Lenz, MD, and Axel Grothey, MD, on Colorectal Cancer: Molecular Testing and Interpreting an NGS Report

Advertisement

Advertisement



Oct
02
Today In Oncology
2-Year Toxicity With Conventional IMRT vs Hypofractionated SBRT for Localized Prostate Cancer
Association of Breast Cancer Recurrence in Patients Achieving pCR With vs Without Residual DCIS After Neoadjuvant Chemotherapy
Tissue vs ctDNA NGS for Detecting Actionable Alterations in Patients With Advanced Cancer
Inflammatory Markers and Clinical Decline After Adjuvant Chemotherapy in Older Women With Breast Cancer
Outcomes After Nonresponse and Relapse in Children/Young Adults Receiving Tisagenlecleucel for B-Cell ALL
View More 
Advertisement
© 2022 HSP News Service, L.L.C.
Designed by Harborside